腹膜透析递增处方:澳加泰三国医护调查揭示实践差异与认知障碍
该研究在澳大利亚、加拿大和泰国开展单位层面在线调查,评估递增式腹膜透析(PD)的使用率、处方模式及医护观点。共收到175个PD单元的254份回复,多数单元递增式PD使用率低于10%,且定义差异显著。医护认为患者满意度提升是主要优势,但患者对剂量升级的抵触是常见障碍。
要点
- 多数PD单元递增式PD使用率低于10%,实践差异大。
- 递增式PD定义缺乏国际共识,常见标准包括CAPD每日<4次交换等。
- 患者或照护者对剂量升级的抵触是主要障碍。
核心结论
- 递增式PD处方不频繁且定义多样,患者对剂量升级的抵触是障碍,需高质量数据指导定义、启动和升级。
研究设计与样本
- 多国单位层面在线调查,含27个关于递增式PD实践的问题,于2023年6月至2025年9月发放给澳大利亚、加拿大和泰国的高级PD单元医护人员。
- 共收到来自175个PD单元的254份回复(澳大利亚62个单元中55个(89%);加拿大82个单元中49个(60%);泰国210个单元中71个(34%))。
主要发现
- 多数单元(56%,P = 0.16)报告递增式PD处方患者比例低于10%。
- 递增式PD定义差异大:CAPD每日<4次交换(75%)、自动化PD或CAPD每周<7天(分别为65%和61%)、CAPD <8 L/d(50%)、单次长夜间交换(46%)、无日间留腹的自动化PD(44%)。
- 报告的优点包括提高患者满意度(81%)、愿意选择PD(75%)和保留残余肾功能(64%)。
- 报告的缺点包括患者或照护者对剂量升级的抵触(62%)和需要更频繁监测(31%)。
- 生活质量被确定为未来研究最重要的领域。
临床怎么用
- 临床可考虑递增式PD,但需注意定义不统一和患者对剂量升级的抵触,并加强监测。
局限性
- 缺乏高质量证据指导安全递增式PD处方,调查结果可能受应答偏倚影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Incremental peritoneal dialysis (PD) is defined as prescribing a less-than-standard PD dose. High-certainty evidence to guide safe incremental PD prescription is lacking, resulting in substantial practice variability. We conducted a multinational survey to evaluate current uptake, practice patterns, and clinician perspectives on incremental PD. An online, unit-level survey, comprising 27 questions on incremental PD practice, was purposively disseminated to senior PD unit staff (physicians and/or nurses) from Australia, Canada, and Thailand between June 2023 and September 2025. A total of 254 responses were received from 175 PD units (Australia: 55 (89%) of 62 units; Canada: 49 (60%) of 82 units; Thailand: 71 (34%) of 210 units). Incremental PD was reported as prescribed in fewer than 10% of patients in most units (56%, P = 0.16). Incremental PD definitions varied substantially: continuous ambulatory PD (CAPD) with <4 daily exchanges (75%), automated PD or CAPD performed <7 days/wk (65% and 61%), CAPD <8 L/d (50%), a single long overnight exchange (46%), or automated PD without a day dwell (44%), highlighting the absence of international consensus. Key reported advantages included increased patient satisfaction (81%), willingness to choose PD (75%), and preservation of residual kidney function (64%). Frequently cited disadvantages included patient or caregiver resistance to dose escalation (62%) and needing more frequent monitoring (31%). Quality of life was identified as the most important area for future research. Incremental PD is prescribed infrequently and variably. Concern about patient resistance to dose escalation is a barrier. High-quality data are needed to guide how incremental PD is defined, initiated, and escalated.
引用
- Burnett CT, McGrath S, Kanjanabuch T, et al. Perceptions and Patterns Associated with Incremental Peritoneal Dialysis Use: Surveying Physicians and Nurses across Australia, Canada, and Thailand. Clin J Am Soc Nephrol. 2026. PMID: 42525796. doi:10.2215/CJN.0000001128
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。